ETFChannel.com
IOVA Description — Iovance Biotherapeutics Inc

Iovance Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of of cell therapies as cancer immunotherapy products. Co.'s key product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition, Co. is investigating the effectiveness and safety of tumor infiltrating lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and peripheral blood lymphocyte therapy for treatment of chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations.

Company Name: 
Iovance Biotherapeutics Inc
Sector: 
Biotechnology
Number of ETFs Holding IOVA: 
29
Total Market Value Held by ETFs: 
$277,947,889.79
Total Market Capitalization: 
$1,583,000,000
% of Market Cap. Held by ETFs: 
17.56%
 ETF   IOVA Weight   IOVA Amount 
 XBI   1.00%   $68,203,320         
 VTI   0.00%   $42,766,214         
 VB   0.03%   $35,693,187         
 IWM   0.07%   $33,033,731         
 VBR   0.05%   $23,660,135         
 ARKG   0.93%   $22,509,865         
 VXF   0.02%   $18,428,246         
 IWN   0.13%   $15,254,872         
 IDNA   2.56%   $4,440,685         
 VHT   0.02%   $3,965,572         
List of all 29 ETFs holding IOVA »
Quotes delayed 20 minutes

Email EnvelopeFree IOVA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (3.64 out of 4)
58th percentile
(ranked higher than approx. 58% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding IOVA | Iovance Biotherapeutics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.